Our mission is to discover, develop and deliver innovative therapies for the treatment of neurodegenerative diseases, autoimmune disorders and hemophilia to patients worldwide. In doing so, our first priority is patient safety. We are committed to continually developing and advancing our approach to best carry out our mission.
We undergo a robust process to create new or improved therapies for patients. Learn more about our product development process.
We invest more than 20 percent of our revenue each year to develop new therapies. We also develop product innovations to enhance our existing therapies, such as the AVONEX PEN™ (interferon beta-1a) and a dose titration regimen, designed to improve the treatment experience of patients. Learn more about our product pipeline.
Patient Safety in Clinical Trials
To ensure new products are safe and effective, all new therapies undergo a stringent process of preclinical and clinical evaluation. Learn more about patient safety in clinical trials.
Patient Safety and Transparency
Patient safety is our top priority. Learn more about our commitment to patient safety and transparency.